Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoietic stem cell transplantation was analyzed. Four-year probability of overall survival (4y-pOS) was 14%. 4y-pOS for 122 children receiving a second haematopoietic stem cell transplantation was 31% and 3% for those that did not (P = <0 center dot 0001). Achievement of a subsequent remission impacted survival (P = <0 center dot 0001). For patients receiving a second transplant survival with or without achieving a subsequent remission was comparable. Graft source (bone marrow vs. peripheral blood stem cells, P = 0 center dot 046) and donor choice (matched family vs. matched unrelated donor, P = 0 center dot 029) positively impacted survival after ...
Survival for children with relapsed T cell acute lymphoblastic leukemia (T-ALL) is poor when treated...
No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cel...
No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cel...
Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoiet...
Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoiet...
Background Post-transplant relapse has a dismal prognosis in children with acute leukemia undergoing...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for patients ...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for patients ...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for patients ...
Outcome data were collected from the European Society for Blood and Marrow Transplantation registry ...
Background Post-transplant relapse has a dismal prognosis in children with acute leukemia undergoing...
Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We...
Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We...
Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We...
We conducted a retrospective study of 155 children who underwent unrelated donor hematopoietic cell ...
Survival for children with relapsed T cell acute lymphoblastic leukemia (T-ALL) is poor when treated...
No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cel...
No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cel...
Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoiet...
Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoiet...
Background Post-transplant relapse has a dismal prognosis in children with acute leukemia undergoing...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for patients ...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for patients ...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for patients ...
Outcome data were collected from the European Society for Blood and Marrow Transplantation registry ...
Background Post-transplant relapse has a dismal prognosis in children with acute leukemia undergoing...
Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We...
Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We...
Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We...
We conducted a retrospective study of 155 children who underwent unrelated donor hematopoietic cell ...
Survival for children with relapsed T cell acute lymphoblastic leukemia (T-ALL) is poor when treated...
No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cel...
No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cel...